Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 197

1.

N-acetylcysteine and contrast-induced nephropathy in primary angioplasty.

Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, De Metrio M, Galli S, Fabbiocchi F, Montorsi P, Veglia F, Bartorelli AL.

N Engl J Med. 2006 Jun 29;354(26):2773-82.

3.

Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction.

Marenzi G, Lauri G, Assanelli E, Campodonico J, De Metrio M, Marana I, Grazi M, Veglia F, Bartorelli AL.

J Am Coll Cardiol. 2004 Nov 2;44(9):1780-5.

4.

Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial.

Fung JW, Szeto CC, Chan WW, Kum LC, Chan AK, Wong JT, Wu EB, Yip GW, Chan JY, Yu CM, Woo KS, Sanderson JE.

Am J Kidney Dis. 2004 May;43(5):801-8.

PMID:
15112170
5.

Role of N-acetylcysteine in prevention of contrast-induced nephropathy after cardiovascular procedures: a meta-analysis.

Misra D, Leibowitz K, Gowda RM, Shapiro M, Khan IA.

Clin Cardiol. 2004 Nov;27(11):607-10.

6.

Does N-acetylcysteine reduce the incidence of contrast-induced nephropathy and clinical events in patients undergoing primary angioplasty for acute myocardial infarction?

Tanaka A, Suzuki Y, Suzuki N, Hirai T, Yasuda N, Miki K, Fujita M, Tanaka T.

Intern Med. 2011;50(7):673-7. Epub 2011 Apr 1.

7.

The prevention of radiocontrast-agent-induced nephropathy by hemofiltration.

Marenzi G, Marana I, Lauri G, Assanelli E, Grazi M, Campodonico J, Trabattoni D, Fabbiocchi F, Montorsi P, Bartorelli AL.

N Engl J Med. 2003 Oct 2;349(14):1333-40.

8.

Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease.

Toso A, Maioli M, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, Manzone C, Amato M, Bellandi F.

Am J Cardiol. 2010 Feb 1;105(3):288-92. doi: 10.1016/j.amjcard.2009.09.026. Epub 2009 Dec 21.

PMID:
20102936
9.

Acetylcysteine and non-ionic isosmolar contrast-induced nephropathy--a randomized controlled study.

Ferrario F, Barone MT, Landoni G, Genderini A, Heidemperger M, Trezzi M, Piccaluga E, Danna P, Scorza D.

Nephrol Dial Transplant. 2009 Oct;24(10):3103-7. doi: 10.1093/ndt/gfp306. Epub 2009 Jun 23.

PMID:
19549691
10.

Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy.

Kinbara T, Hayano T, Ohtani N, Furutani Y, Moritani K, Matsuzaki M.

J Cardiol. 2010 Mar;55(2):174-9. doi: 10.1016/j.jjcc.2009.10.006. Epub 2009 Dec 1.

11.

Intrarenal application of N-acetylcysteine for the prevention of contrast medium-induced nephropathy in primary angioplasty.

Aslanger E, Uslu B, Akdeniz C, Polat N, Cizgici Y, Oflaz H.

Coron Artery Dis. 2012 Jun;23(4):265-70. doi: 10.1097/MCA.0b013e328351aacc.

PMID:
22343798
12.

N-acetylcysteine and contrast-induced nephropathy.

Balderramo DC.

N Engl J Med. 2006 Oct 5;355(14):1498-9; author reply 1499-500. No abstract available.

PMID:
17024740
13.

Acetylcysteine and contrast agent-associated nephrotoxicity.

Briguori C, Manganelli F, Scarpato P, Elia PP, Golia B, Riviezzo G, Lepore S, Librera M, Villari B, Colombo A, Ricciardelli B.

J Am Coll Cardiol. 2002 Jul 17;40(2):298-303.

14.

Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS--a multicenter prospective controlled trial.

Koc F, Ozdemir K, Kaya MG, Dogdu O, Vatankulu MA, Ayhan S, Erkorkmaz U, Sonmez O, Aygul MU, Kalay N, Kayrak M, Karabag T, Alihanoglu Y, Gunebakmaz O.

Int J Cardiol. 2012 Mar 22;155(3):418-23. doi: 10.1016/j.ijcard.2010.10.041. Epub 2010 Nov 23.

PMID:
21106264
16.

Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality.

Marenzi G, Assanelli E, Campodonico J, Lauri G, Marana I, De Metrio M, Moltrasio M, Grazi M, Rubino M, Veglia F, Fabbiocchi F, Bartorelli AL.

Ann Intern Med. 2009 Feb 3;150(3):170-7.

PMID:
19189906
17.

Contrast medium induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome: differences in STEMI and NSTEMI.

Wickenbrock I, Perings C, Maagh P, Quack I, van Bracht M, Prull MW, Plehn G, Trappe HJ, Meissner A.

Clin Res Cardiol. 2009 Dec;98(12):765-72. doi: 10.1007/s00392-009-0058-5. Epub 2009 Oct 23.

PMID:
19851800
18.

Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.

Oldemeyer JB, Biddle WP, Wurdeman RL, Mooss AN, Cichowski E, Hilleman DE.

Am Heart J. 2003 Dec;146(6):E23.

PMID:
14661012
19.

Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention.

Spargias K, Alexopoulos E, Kyrzopoulos S, Iokovis P, Greenwood DC, Manginas A, Voudris V, Pavlides G, Buller CE, Kremastinos D, Cokkinos DV.

Circulation. 2004 Nov 2;110(18):2837-42. Epub 2004 Oct 18. Erratum in: Circulation. 2005 Jan 25;111(3):379. Iacovis, Panagiotis [corrected to Iokovis,Panagiotis].

20.

Acetylcysteine In Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics.

Coyle LC, Rodriguez A, Jeschke RE, Simon-Lee A, Abbott KC, Taylor AJ.

Am Heart J. 2006 May;151(5):1032.e9-12.

PMID:
16644332

Supplemental Content

Support Center